These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6333565)

  • 21. The pathology and homing of a transplantable murine B cell leukemia (BCL1).
    Warnke RA; Slavin S; Coffman RL; Butcher EC; Knapp MR; Strober S; Weissman IL
    J Immunol; 1979 Sep; 123(3):1181-8. PubMed ID: 381519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses.
    Anderson SA; Isakson PC; Puré E; Muirhead M; Uhr JW; Vitetta ES
    J Immunol; 1981 Apr; 126(4):1603-7. PubMed ID: 6451649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1).
    Morecki S; Pugatsch T; Levi S; Moshel Y; Slavin S
    Int J Cancer; 1996 Jan; 65(2):204-8. PubMed ID: 8567118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the spleen in the growth of a murine B cell leukemia.
    Kotzin BL; Strober S
    Science; 1980 Apr; 208(4439):59-61. PubMed ID: 6965803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.
    Kovar M; Tomala J; Chmelova H; Kovar L; Mrkvan T; Joskova R; Zakostelska Z; Etrych T; Strohalm J; Ulbrich K; Sirova M; Rihova B
    Cancer Res; 2008 Dec; 68(23):9875-83. PubMed ID: 19047168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoid effects on lipopolysaccharide-stimulated murine B-cell leukemia line (BCL1) cells.
    Roess DA; Ruh TS; Bellone CJ; Ruh MF
    Cancer Res; 1983 Jun; 43(6):2536-40. PubMed ID: 6601983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor mediated leukemogenesis: murine leukemia virus interacts with BCL1 lymphoma cell surface IgM.
    McGrath MS; Tamura G; Weissman IL
    J Mol Cell Immunol; 1987; 3(4):227-42. PubMed ID: 2855408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen presentation by the BCL1 murine B cell line: in vitro stimulation by LPS.
    Harris MR; Kindle CS; Abruzzini AF; Pierce CW; Cullen SE
    J Immunol; 1984 Sep; 133(3):1202-8. PubMed ID: 6611366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new in vivo and in vitro B cell lymphoma model, pi-BCL1.
    Illidge T; Honeychurch J; Howatt W; Ross F; Wilkins B; Cragg M
    Cancer Biother Radiopharm; 2000 Dec; 15(6):571-80. PubMed ID: 11190489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in murine B-cell leukemia (BCL1) detected by PCR.
    Pugatsch T; Weiss L; Slavin S
    Leuk Res; 1993 Nov; 17(11):999-1002. PubMed ID: 8231239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex.
    Siu H; Vitetta ES; May RD; Uhr JW
    J Immunol; 1986 Aug; 137(4):1376-82. PubMed ID: 3525678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).
    Loewenthal E; Weiss L; Samuel S; Or R; Slavin S
    Bone Marrow Transplant; 1993 Aug; 12(2):109-13. PubMed ID: 8401354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL; Forman J
    J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of leukemic cell proliferation by one or more factors released from splenic BCL1 cells.
    Bessler H; Hart J; Slavin S; Djaldetti M
    Exp Hematol; 1995 Dec; 23(13):1353-7. PubMed ID: 7498363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-1a cell origin of the murine B lymphoma line BCL1 characterized by surface markers and bacterial reactivity of its surface IgM.
    Koganei S; Ito M; Yamamoto K; Matsumoto N
    Immunol Lett; 2005 May; 98(2):232-44. PubMed ID: 15860223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of BCL1 cells by polyclonal activators and inhibition of growth and IgM secretion by anti-IgM.
    Severinson E; Torres A; Möller G
    Scand J Immunol; 1983 Aug; 18(2):153-62. PubMed ID: 6192491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR.
    Knapp MR; Jones PP; Black SJ; Vitetta ES; Slavin S; Strober S
    J Immunol; 1979 Sep; 123(3):992-9. PubMed ID: 313960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.